QC
BDTX icon

Quadrature Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Quadrature Capital’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.8K Buy
+37,474
New +$89.1K ﹤0.01% 1252
2025
Q4 		– Sell
-11,366
Closed -$43.1K – 1265
2025
Q3 		$43.1K Buy
+11,366
New +$33.2K ﹤0.01% 964

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Quadrature Capital's BDTX Position: Q1 2026 in Review

Quadrature Capital opened a new position in Black Diamond Therapeutics (BDTX) in Q1 2026: 37,474 shares worth $79.8K. The stake represents ﹤0.01% of the portfolio and ranks #1252 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in BDTX as recently as Q3 2025.

Quadrature Capital first reported a position in BDTX in Q3 2025 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Quadrature Capital held 37,474 shares of Black Diamond Therapeutics worth $79.8K as of Q1 2026.
  • Black Diamond Therapeutics was a new Quadrature Capital position in Q1 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1252 holding.
  • Quadrature Capital first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.